Retina/Vitreous News

Healio spoke with Bradley Dougherty, OD, PhD, associate professor at The Ohio State University College of Optometry, about how socioeconomic factors can affect the diagnosis, treatment and outcomes of age-related macular degeneration.

A questionnaire found that the majority of retina fellows planned to go into a retina-only private practice.

Eclipse Life Sciences has enrolled and dosed the first patient in the BETTIS-1 phase 2 clinical trial investigating the EC-104 implant for the treatment of diabetic macular edema, according to a press release.

An AI program accurately identified posterior vitreous opacities in patients with posterior vitreous detachments, which may improve screening for retinal tears, according to a study.

The progression of myopia among school-aged children in China appeared to primarily affect changes in inner retinal thickness over the course of 1 year, according to research.

The FDA approved the Enzeevu 2 mg vial kit and prefilled syringe for intravitreal injection for the treatment of neovascular age-related macular degeneration, according to a press release from Sandoz.

When managing myopic traction maculopathy, the timing of surgery should be carefully evaluated, avoiding early or delayed intervention, according to a speaker at the American Society of Retina Specialists annual meeting.

In this Healio Video Perspective from the ASRS meeting, Michael A. Singer, MD, of the University of Texas Health Science Center in San Antonio, discusses topline results for MCO-010 for the treatment of retinitis pigmentosa.

While the prevalence of blindness due to age-related macular degeneration decreased globally from 2000 to 2020, researchers warn that the social and economic impact of AMD may grow as the population ages.

Ocular Therapeutix obtained FDA support to use the phase 3 SOL-R trial as the next step in the regulatory process for Axpaxli, according to a press release.